OBJECTIVE: AT-rich interactive domain 1A (ARID1A) has recently been identified as a novel tumor suppressor in various tumor types. This study was designed to explore the clinical relevance and prognostic impact of ARID1A expression loss in colorectal cancer (CRC) and gastric cancer (GC). METHODS: Immunohistochemistry for ARID1A was performed using tissue microarray blocks containing 196 CRCs and 275 GCs, along with paired normal mucosa. Data on clinicopathologic variables and oncologic outcomes of patients were collected and analyzed. RESULTS: We identified 6.1% (12/196) CRC and 8.0% (22/275) GC cases showing loss of ARID1A expression. Expression of ARID1A in paired mucosal epithelial cells was normal in all patients. Loss of ARID1A expression was significantly correlated with negative lymphatic invasion (p = 0.003) in CRC, with large tumor size (p = 0.037) in GC, and with expanding tumor border in both tumor types (CRC, p = 0.010; GC, p = 0.031). However, no association was evident between ARID1A expression and 5-year overall survival in both tumor types. CONCLUSIONS: Loss of ARID1A expression is uncommon and not associated with oncologic outcome but may be related to less invasive clinicopathologic features in CRC and GC. Further studies with a larger number of subjects are needed to establish the possible prognostic impact of ARID1A expression loss.
OBJECTIVE:AT-rich interactive domain 1A (ARID1A) has recently been identified as a novel tumor suppressor in various tumor types. This study was designed to explore the clinical relevance and prognostic impact of ARID1A expression loss in colorectal cancer (CRC) and gastric cancer (GC). METHODS: Immunohistochemistry for ARID1A was performed using tissue microarray blocks containing 196 CRCs and 275 GCs, along with paired normal mucosa. Data on clinicopathologic variables and oncologic outcomes of patients were collected and analyzed. RESULTS: We identified 6.1% (12/196) CRC and 8.0% (22/275) GC cases showing loss of ARID1A expression. Expression of ARID1A in paired mucosal epithelial cells was normal in all patients. Loss of ARID1A expression was significantly correlated with negative lymphatic invasion (p = 0.003) in CRC, with large tumor size (p = 0.037) in GC, and with expanding tumor border in both tumor types (CRC, p = 0.010; GC, p = 0.031). However, no association was evident between ARID1A expression and 5-year overall survival in both tumor types. CONCLUSIONS: Loss of ARID1A expression is uncommon and not associated with oncologic outcome but may be related to less invasive clinicopathologic features in CRC and GC. Further studies with a larger number of subjects are needed to establish the possible prognostic impact of ARID1A expression loss.
Authors: Lik Hang Lee; Eran Sadot; Sinisa Ivelja; Efsevia Vakiani; Jaclyn F Hechtman; Christopher J Sevinsky; David S Klimstra; Fiona Ginty; Jinru Shia Journal: Hum Pathol Date: 2016-03-02 Impact factor: 3.466
Authors: Claudio Luchini; Nicola Veronese; Marco Solmi; Hanbyoul Cho; Jae-Hoon Kim; Angela Chou; Anthony J Gill; Sheila F Faraj; Alcides Chaux; George J Netto; Kentaro Nakayama; Satoru Kyo; Soo Young Lee; Duck-Woo Kim; George M Yousef; Andreas Scorilas; Gregg S Nelson; Martin Köbel; Steve E Kalloger; David F Schaeffer; Hai-Bo Yan; Feng Liu; Yoshihito Yokoyama; Xianyu Zhang; Da Pang; Zsuzsanna Lichner; Giuseppe Sergi; Enzo Manzato; Paola Capelli; Laura D Wood; Aldo Scarpa; Christoph U Correll Journal: Oncotarget Date: 2015-11-17
Authors: Hyun Deuk Cho; Jong Eun Lee; Hae Yoen Jung; Mee-Hye Oh; Ji-Hye Lee; Si-Hyong Jang; Kyung-Ju Kim; Sun Wook Han; Sung Yong Kim; Han Jo Kim; Sang Byung Bae; Hyun Ju Lee Journal: J Breast Cancer Date: 2015-12-23 Impact factor: 3.588